A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 4, 2013, Pages 328-337

  Tomic, Karen ^a   Long, Stacey ^b   Li, Xiaoyan ^c   Fu, An Chen ^d   Yu, Tzy Chyi ^d   Barron, Richard ^c  

^a Oxford PharmaGenesis Inc   (United States)

^b IBM WATSON HEALTH   (United States)

^c AMGEN INC   (United States)

^d HEALTHCORE INC   (United States)

Author keywords

claims database; filgrastim; granulocyte colony stimulating factors; Out of pocket costs; pegfilgrastim

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HEALTH INSURANCE ELIGIBILITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

CLAIMS DATABASE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTORS; OUT-OF-POCKET COSTS; PEGFILGRASTIM;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; FEVER; FINANCING, PERSONAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84888107431     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212473001     Document Type: Article

References (31)

1. Bradley CJ. Financial hardship: a consequence of survivorship?. J Clin Oncol. 2012 ; 30: 1579-1580
2. Macready N. The climbing costs of cancer care. J Natl Cancer Inst. 2011 ; 103: 1433-1435
3. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011 ; 7: 46s - 51s
4. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007 ; 25: 180-186
5. Pisu M, Azuero A, McNees P, et al. The out of pocket cost of breast cancer survivors: A review. J Cancer Survivor. 2010 ; 4: 202-209
6. Arozullah AM, Calhoun EA, Wolf M, et al. The financial burden of cancer: estimates from a study of insured women With breast cancer. J Support Oncol. 2004 ; 2: 271-278
7. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011 ; 29: 2821-2826
8. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 ; 106: 2258-2266
9. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 ; 25: 3158-3167
10. NEUPOGEN® (Filgrastim) prescribing information, Amgen.
11. Neulasta® (pegfilgrastim) prescribing information, Amgen.
12. Hecht JR, Pillai M, Gollard R, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 ; 9: 95-101
13. NCCN. National Comprehensive Cancer Network: NCCN Clinical Guidelines in Oncology. Myeloid Growth Factors. NCCN v1.2012.
14. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 ; 24: 3187-3205
15. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011 ; 47: 8-32
16. Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007 ; 13: 337-348
17. Scott SD, Chrischilles EA, Link BK, et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm. 2003 ; 9: 15-21
18. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008 ; 19: 292-298
19. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002 ; 20: 727-731
20. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 ; 14: 29-35
21. Lyman GH. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin Biol Ther. 2005 ; 5: 1635-1646
22. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?. Ann Pharmacother. 2006 ; 40: 402-407
23. Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009 ; 31: 1069-1081
24. Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol. 2012 ; 35: 267-274
25. Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin. 2011 ; 27: 79-86
26. Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 ; 3: 36-46
27. Tan Sean P, Chouaid C, Hettler D, et al. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Curr Med Res Opin. 2009 ; 25: 1455-1460
28. Fortner BV, Tauer KT, Zhu L, et al. The impact of anemia and neutropenia treatment visits on patients and their caregivers. Poster presented at: 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 8 - 11 December 2004, Abstract 6031.
29. Fortner BV, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer. 2004 ; 4: 22-22
30. Haithcox SR, Ramnes C, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs. 2003 ; 2: 2-2
31. Dor A, Lage MJ, Tarrants ML, et al. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. Adv Health Econ Health Serv Res. 2010 ; 22: 175-193